Jad Chahoud, Chief Scientific and Innovation Officer at Orlando Health Cancer Institute, shared a post on LinkedIn:
“EV + Pembrolizumab delivers another positive trial in MIBC
Pfizer just announced positive EFS and OS results for enfortumab vedotin (EV) + pembrolizumab in muscle-invasive bladder cancer (MIBC) — this time versus chemotherapy + surgery, not surgery alone.
A very exciting moment for bladder cancer! Congrats to our patients and the study PIs more data to come!”
Read the full press release.
More posts about Bladder Cancer.